Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ischemic stroke patients are biologically older than their chronological age

  • Soriano Tárraga, Carolina|||0000-0002-5635-273X
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Mola-Caminal, Marina
  • Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
  • Ois, Angel|||0000-0002-1375-5950
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Cuadrado Godia, Elisa|||0000-0002-9147-875X
  • Sayols-Baixeras, Sergi
  • Elosua, Roberto|||0000-0001-8235-0095
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
Ischemic stroke is associated with aging. It is possible to predict chronological age by measuring age-related changes in DNA methylation from multiple CpG sites across the genome, known as biological age. The difference between biological age and actual chronological age would indicate an individual's level of aging. Our aim was to determine the biological age of ischemic stroke patients and compare their aging with controls of the same chronological age. A total of 123 individuals, 41 controls and 82 patients with ischemic stroke were paired by chronological age, ranging from 39 to 82 years. Illumina HumanMethylation450 BeadChip array was used to measure DNA methylation in CpG sites in both groups, and biological age was estimated using methylation values of specific CpGs. Ischemic stroke patients were biologically an average 2.5 years older than healthy controls (p-value=0.010). Stratified by age tertiles, younger stroke patients (≤57 years old) were biologically older than controls (OR=1.19; 95%CI 1.00-1.41, p-value=0.046). The older groups showed no biological age differences between cases and controls, but were close to reaching the significance level. Ischemic stroke patients are biologically older than controls. Biological age should be considered as a potential new biomarker of stroke risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era, beyond myocardial mechanical reperfusion

  • Ribas Barquet, Núria|||0000-0003-1492-5285
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Meroño, Oona
  • Recasens, Lluís
  • Pérez-Fernández, Silvia|||0000-0002-9756-0092
  • Bazán, Víctor|||0000-0001-8072-7434
  • Salvatella, Neus
  • Martí Almor, Julio|||0000-0001-9927-1190
  • Bruguera Cortada, Jordi
  • Elosua, Roberto|||0000-0001-8235-0095
The AMI code is a regional network enhancing a rapid and widespread access to reperfusion therapy (giving priority to primary angioplasty) in patients with acute ST-segment elevation myocardial infarction (STEMI). We aimed to assess the long-term control of conventional cardiovascular risk factors after a STEMI among patients included in the AMI code registry. Four hundred and fifty-four patients were prospectively included between June-2009 and April-2013. Clinical characteristics were collected at baseline. The long-term control of cardiovascular risk factors and cardiovascular morbidity/mortality was assessed among the 6-months survivors. A total of 423 patients overcame the first 6 months after the STEMI episode, of whom 370 (87%) underwent reperfusion therapy (363, 98% of them, with primary angioplasty). At 1-year follow-up, only 263 (62%) had adequate blood pressure control, 123 (29%) had LDL-cholesterol within targeted levels, 126/210 (60%) smokers had withdrawn from their habit and 40/112 (36%) diabetic patients had adequate glycosylated hemoglobin levels. During a median follow-up of 20 (11-30) months, cumulative mortality of 6 month-survivors was 6.1%, with 9.9% of hospital cardiovascular readmissions. The lack of assessment of LDL and HDL-cholesterol were significantly associated with higher mortality and cardiovascular readmission rates. Whereas implementation of the AMI code resulted in a widespread access to rapid reperfusion therapy, its long-term therapeutic benefit may be partially counterbalanced by a manifestly suboptimal control of cardiovascular risk factors. Further efforts should be devoted to secondary prevention strategies after STEMI. The online version of this article (doi:10.1186/s12872-017-0493-6) contains supplementary material, which is available to authorized users.